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Reduction of trimethylamine N-oxide to trimethylamine by the human gut 
microbiota: supporting evidence for ‘metabolic retroversion’ 
 Feeding trimethylamine N-oxide (TMAO; found in fish) to individuals with 
fish odour syndrome (FOS), in which trimethylamine (TMA) is not detoxified to 
TMAO by hepatic flavin-containing monooxygenases (FMOs), leads to 
conversion of 40–60 % of the oral dose of TMAO to TMA [1]. In these 
individuals, it is thought the gut microbiota reduces TMAO to TMA, and in those 
individuals without FOS the TMA is re-oxidized in the liver before being excreted 
in the urine. The process has been termed ‘metabolic retroversion’ [1] (Fig. 1). 
We examined the bioconversion of TMAO to TMA by the microbiota using in 
vitro systems, and mouse models to determine whether ‘metabolic retroversion’ 
of TMAO occurred in vivo. 
 
 
 
 
 
 
 
 Strains (n = 66) of human faecal and caecal bacteria were screened on 
solid and liquid media [2] anaerobically at 37 °C for their ability to reduce TMAO, 
with metabolites in spent media analysed by 1H-NMR. Effects of TMAO on 
mixed microbial growth was assessed using in vitro anaerobic, stirred, pH-
controlled batch-culture fermentation systems inoculated with human faeces. 
Groups of 6-week-old C57Bl6/J mice were given free access to either tap water 
or tap water treated with a broad-spectrum antibiotic cocktail for 14 days. Mice 
were given in the morning by gavage either a solution of d9-TMAO (Cambridge 
Isotope Laboratories, Inc.) or saline and euthanized 6 h later by cervical 
dislocation. Plasma samples were collected and stored at -80 °C. Ultra 
Performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS) 
was used to determine concentrations of TMA, d9-TMA, TMAO and d9-TMAO in 
samples [3].    
 TMAO significantly increased the growth rate of Enterobacteriaceae (Fig. 
2a–c). While having no effect on the growth rate of lactic acid bacteria (Fig. 
2d,e), TMAO had a significant effect on biomass produced by these bacteria 
(not shown) and led to increased production of lactate (Fig. 3). As only 
negligible levels of TMA were produced from TMAO by these bacteria, they 
were not using TMAO as an alternative electron acceptor in anaerobic 
respiration. 
 In mixed microbial populations, only the growth of Enterobacteriaceae was 
promoted in the presence of TMAO (Fig. 4a), with TMA produced only in the 
TMAO-containing systems (Fig. 4b). 
 In vivo ‘metabolic retroversion’ of TMAO was confirmed in mice (Fig. 5), 
demonstrating that choline, phosphatidylcholine and carnitine [4–6] are not the 
only dietary sources of TMA with the potential to influence host metabolism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the absence of the microbiota, TMAO is taken up by the host into the 
circulation by an unknown mechanism. Elucidating this mechanism, and 
examining the effects of TMAO on lactic acid bacteria in greater detail are the 
focus of ongoing work. 
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Fig. 2. Effect of TMAO on growth of gut bacteria. (a) 
Escherichia coli; (b) Citrobacter gillenii; (c) Klebsiella 
pneumoniae; (d) Enterococcus gallinarum; (e) 
Streptococcus anginosus; (f) Clostridium perfringens. 
Representative results are given (mean +/- SD, n = 
3). Red, growth medium with 1 % TMAO; blue, 
growth medium without TMAO.  
Fig. 3. Lactate production by lactic acid bacteria compared 
with that of members of the family Enterobacteriaceae in the 
presence of TMAO. Enterobacteriaceae, n = 20; 
Bifidobacteriaceae, n = 17; Streptococcaceae, n = 7; 
Enterococcaceae, n = 5. Two strains belonging to the 
Lactobacillaceae also produced increased amounts (6.96 ± 
1.35 mM and 0.17 ± 0.07 mM, respectively) of lactic acid and 
TMA in the presence of TMAO (data not shown). Red, TMAO-
containing medium; blue, negative control. *, Statistically 
significantly different (t test) from its negative control (adjusted 
P value < 0.05). Results are shown as mean +/- SD. 
Fig. 1. ‘Metabolic retroversion’: the reduction of TMAO 
to TMA by the gut microbiota, followed by oxidative 
reactions mediated by hepatic FMOs to regenerate 
TMAO [1]. TMAO is reduced by gut bacteria to TMA in 
the small intestine and proximal colon. TMA is taken up 
by the hepatic portal vein to the liver, where it is N-
oxidized into TMAO by hepatic flavin mono-
oxygenases (FMO) and demethylated into 
dimethylamine and monomethylamine by cytochrome 
P450s during first-pass metabolism. TMAO (and minor 
amounts of TMA) are excreted in the urine. 
Fig. 4. Effect of TMAO on mixed faecal microbial populations in vitro. 
(a) Enumeration of bacteria in fermentation vessels by FISH analysis. 
(b) NMR data for batch culture samples. (a, b) Red lines, TMAO-
containing systems; blue lines, negative controls. Data are shown as 
mean +/- SD (n = 3). *, Statistically significantly different (P < 0.05) 
from the negative control at the same time point.  
(a) (b) 
Fig. 5. In vivo confirmation of ‘metabolic retroversion’ of TMAO in a mouse model. Retroversion of d9-TMAO into d9-TMA was 
quantified by UPLC-MS up to 6 h after d9-TMAO gavage and antibiotic treatment, together with endogenous TMA and TMAO 
production. Data (n = 6 animals per group) are shown as mean ± SEM. (a, b, e, f) *, significantly different (P < 0.05; t test and 
corrected for multiple testing) from the respective control not treated with. (c, d, g, h) Differences between the groups were 
assessed using one-way analysis of variance (ANOVA), followed by post hoc tests. Data with different superscript letters are 
significantly different (P < 0.05). (a) Plasma quantification of post-gavage d9-TMA. (b) Plasma quantification of post-gavage 
d9-TMAO. (c) d9-TMA bioavailability [area under the curve (AUC)]. (d) d9-TMAO bioavailability (AUC). (e) Plasma 
quantification of post-gavage endogenous TMA. (f) Plasma quantification of post-gavage endogenous TMAO. (g) 
Endogenous TMA bioavailability (AUC). (h) Endogenous TMAO bioavailability (AUC). 
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